Comprehensive analysis of adverse event profile changes with pertuzumab addition to trastuzumab‐based breast cancer therapy: Disproportionality analysis using VigiBase
AE profiles after the addition of pertuzumab to trastuzumab-based therapy were comprehensively identified. The findings in this study highlight the importance of considering these AEs when selecting pertuzumab combination therapy to ensure the safety of patients with breast cancer.
Authors
- Yoshito Zamami (ORCID: https://orcid.org/0000-0002-7879-423X)
- Jun Matsumoto (ORCID: https://orcid.org/0000-0001-7224-108X)
- Takehiko Sakai (ORCID: https://orcid.org/0000-0002-4982-951X)
- Hirofumi Hamano (ORCID: https://orcid.org/0000-0002-2231-0179)
- Toshihiro Koyama (ORCID: https://orcid.org/0000-0002-7755-1754)
- Naohiro Iwata
- Tatsuaki Takeda (ORCID: https://orcid.org/0000-0002-9872-2559)
- Noritaka Ariyoshi
Institutions
- Okayama University (JP)
- Okayama University Hospital (JP)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-05-08
- DOI
- https://doi.org/10.1002/bcp.70094
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05